Is CagriSema the same as Wegovy?

No. Wegovy is a brand name for semaglutide alone. CagriSema is a fixed combination of cagrilintide plus semaglutide in one weekly injection. Semaglutide alone, as Wegovy 2.4 milligrams, produced 14.9% at 68 weeks in STEP 1. Cagrilintide alone produced 6.0% to 10.8% at 26 weeks in 706 people versus 3.0% on placebo. Together, a Phase 2 trial in 92 adults with type 2 diabetes found 15.6% at 32 weeks versus 5.1% on semaglutide alone. CagriSema remains investigational. Wegovy is an approved weight-management brand. The shared molecule is one half of CagriSema, not the whole product. This site does not rank them. Full record at /compounds/cagrilintide.

Educational use only. This database summarizes published research and is not medical advice. Where a dose appears it is a record of what a trial or clinic ran, or what people describe doing, with its source attached. Nothing here is a recommendation for personal use.

Part of glp-1 and metabolic peptides. Semaglutide, tirzepatide, retatrutide, and the rest of the incretin and glucagon receptor family.